Recommended

EU-India conclude Free Trade Agreement
Pennsylvania to home Lilly fourth new US manufacturing facility
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
WEBINAR | Practical considerations for aseptic gowning in contamination control strategies
AstraZeneca commits $15bn to Chinese manufacturing
Roche GLP-1 promising in phase II obesity trial
WuXi Biologics and HanchorBio collaborate on next-gen immunotherapies
Innovative nanoparticle research potential AMR breakthrough
Harnessing digital PCR for rapid sterility testing | WEBINAR
Realising autonomous pharmaceutical operations – register now
Explore the latest issue here
Complying with USP Chapters 41 and 1251 revisions for pharma quality control | WEBINAR
news

Dr Michael J. Miller joins Spore.Bio as VP of Scientific and Regulatory Affairs

1
SHARES

The French start-up focuses on advancing rapid microbiology in manufacturing quality control.

Spore.Bio's Amine Raji and Dr Michael J Miller

Spore.Bio has appointed Dr Michael J. Miller (pictured above right) as its VP of Scientific and Regulatory Affairs as it seeks to embed rapid, modern microbiology in pharma manufacturing and other highly regulated industries.

 

SECURE YOUR FREE SPOT

 


This webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing | 18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

A Q&A session at the end of the webinar gives the audience a chance to ask questions, such as how to implement these technologies effectively.

Register now – it’s free

An internationally recognised expert in rapid microbiological methods and contamination control, Dr Miller has nearly 40 years of experience in pharmaceutical microbiology, contamination control and the validation of rapid microbiological methods.

During that time he has held senior and executive roles in microbiology at Johnson & Johnson, Lilly and Bausch & Lomb.

“Spore.Bio is tackling a problem I’ve spent my entire career thinking about: how to make microbiology faster, more reliable, and more actionable for manufacturers,” he said.

“The combination of AI, biophotonics and microbiology Spore.Bio is building has the potential to redefine what ‘rapid methods’ mean. I’m excited to work with a firm that continues to set the standard for what a scientifically robust, validated and regulated platform can bring to users across pharma and beyond.”

In addition to advising the USP Microbiology Expert Committee, Dr Miller has authored more than 100 technical publications and presentations and is the chairperson for the revision of PDA Technical Report No. 33 – created to establish industry-wide criteria on what constitutes an acceptable alternative or rapid microbiology test.

Spore.Bio’s CEO Amine Raji (pictured above left) said: “Bringing the biggest key opinion leader of our field into Spore.Bio is a strong signal of where we’re headed as a company. His decades of experience in rapid methods, contamination control and regulatory strategy give us exactly the kind of scientific and regulatory backbone we need as we scale.”

Paris-headquartered Spore.Bio was founded in 2023 by Amine Raji, Maxime Mistretta (CTO) and Mohamed Tazi (COO) and, with its reagent free, AI driven microbiology platform for real time contamination monitoring, aims to disrupt microbiology testing technology.

 
Share via
Share via